Pharmacokinetics of Piperacillin-Tazobactam in Anuric Intensive Care Patients during Continuous Venovenous Hemodialysis-Reference-Cited by-同舟云学术

Pharmacokinetics of Piperacillin-Tazobactam in Anuric Intensive Care Patients during Continuous Venovenous Hemodialysis

Published:2002-05 Issue:5 Volume:46 Page:1557-1560
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Mueller Silke C.¹,Majcher-Peszynska Jolanta¹,Hickstein Heiko²,Francke Astrid³,Pertschy Annette⁴,Schulz Martin²,Mundkowski Ralf¹,Drewelow Bernd¹

Affiliation:

1. Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology

2. Clinic for Internal Medicine

3. Clinic for Anesthesiology and Intensive Care Medicine

4. Clinic for Surgery, University of Rostock, D-18057 Rostock, Germany

Abstract

ABSTRACT The pharmacokinetics of piperacillin-tazobactam were investigated in eight anuric intensive care patients treated by continuous venovenous hemodialysis (CVVHD). The elimination half-life of piperacillin was 4.3 ± 1.2 h, and that of tazobactam was 5.6 ± 1.3 h. The contribution of CVVHD to the overall elimination was relevant (>25%) for both drugs.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.46.5.1557-1560.2002

Reference21 articles.

1. Piperacillin and Tazobactam Exhibit Linear Pharmacokinetics after Multiple Standard Clinical Doses

2. Daniel, K. P., and L. C. Krop. 1996. Piperacillin-tazobactam: a new β-lactam-β-lactamase inhibitor combination. Pharmacotherapy16:149-162.

3. Derendorf, H., and T. Dalla Costa. 1996. Pharmacokinetics of piperacillin, tazobactam and its metabolite in renal impairment. Int. J. Clin. Pharmacol. Ther.34:482-488.

4. Halsstensen, C. E., M. O. Wong, C. A. Johnson, S. W. Zimmerman, J. J. Onorato, W. F. Keane, M. Doepner, L. Sia, K. Tantillo, S. Bansal, O. Kuye, A. Yacobi, R. Faulkner, and C. D. Lathia. 1994. Pharmacokinetics of tazobactam M1 metabolite after administration of piperacillin/tazobactam in subjects with renal impairment. J. Clin. Pharmacol.34:1208-1217.

5. Heinzel G. R. Woloszczak and P. Thomann. 1993. Topfit 2.0: pharmacokinetic and pharmacodynamic data analysis system for PC. Gustav Fischer Verlag Stuttgart Germany.

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibiotic dosing recommendations in critically ill patients receiving new innovative kidney replacement therapy;BMC Nephrology;2024-02-27

2. Piperacillin‐tazobactam dosing in anuric acute kidney injury patients receiving continuous renal replacement therapy;Seminars in Dialysis;2023-02-20

3. Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model againstKlebsiella pneumoniae—authors’ response;Journal of Antimicrobial Chemotherapy;2023-01-30

4. Pharmacokinetic and Pharmacodynamic Basis of Optimal Antimicrobial Therapy;Principles and Practice of Pediatric Infectious Diseases;2023

5. Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children Receiving Continuous Renal Replacement Therapy;Antimicrobial Agents and Chemotherapy;2022-12-20